MCE products for research use only. We do not sell to patients.

Ixekizumab

MCE China：Ixekizumab

Brand：MedChemExpress (MCE)

Cat. No.HY-P9924

CAS：1143503-69-8

Synonyms：LY2439821

Purity：99.00%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Description：Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KDIL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.

In Vitro：The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A[1]. Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion[1].

In Vivo：Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner[1]. In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 μg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days[1].

IC50 & Target：IL-17

Species：Humanized

Isotype：Human IgG4 kappa

Recommend Isotype Controls：Human IgG4 (S228P) kappa, Isotype Control

Hot selling product：HRP-conjugated AffiniPure Goat Anti-Rabbit IgG H&L   | Motavizumab  | Mirabegron  | L-Ascorbic acid (sodium salt)  | Larotrectinib  | DiZPK  | Ciliobrevin D  | Citric acid  | Dioscin  | Neutral protease from paenibacillus polymyxa

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19.  [Content Brief]

[2]. Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.  [Content Brief]